Additionally, therapies targeting B cell receptor signaling pathways, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or the phosphoinositide 3-kinase (PI3K) inhibitor idelalisib, have shown efficacy in not only controlling CLL but also addressing associated autoimmune manifestations23–25. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.